Restorative effects of hydroxysafflor yellow A on hepatic function in an experimental regression model of hepatic fibrosis induced by carbon tetrachloride

Li,Yanuo; Shi,Yan; Sun,Yan; Liu,Luying; Bai,Xianyong; Wang,Dong; Li,Hongxing

doi:10.3892/mmr.2016.5965

Restorative effects of hydroxysafflor yellow A on hepatic function in an experimental regression model of hepatic fibrosis induced by carbon tetrachloride

Authors:
- Yanuo Li
- Yan Shi
- Yan Sun
- Luying Liu
- Xianyong Bai
- Dong Wang
- Hongxing Li
View Affiliations

Affiliations: Department of Histology and Embryology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Department of Osteology, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Department of Pathology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: November 24, 2016 https://doi.org/10.3892/mmr.2016.5965
Pages: 47-56
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic fibrosis is a reversible pathological process, in which fibrotic tissue is excessively deposited in the liver during the repair process that follows hepatic injury. Early prevention or treatment of hepatic fibrosis has great significance on the treatment of chronic hepatic diseases. Hydroxysafflor yellow A (HSYA) is a water-soluble monomer extracted from safflower, which serves numerous pharmacological roles. However, it remains to be elucidated how HSYA regulates hepatic fibrogenesis. The aim of the present study was to reveal the possible mechanisms underlying the effects of HSYA on the prevention and treatment of hepatic fibrosis. A rat model of hepatic fibrosis was established in the present study, and the rats were administered various doses of HSYA. The effects of HSYA on pathological alterations of the liver tissue in rats with hepatic fibrosis were observed using hematoxylin-eosin staining and Masson staining. In order to explore the anti‑hepatic fibrosis effects and underlying mechanisms of HSYA, serum levels, and hepatic function and hepatic fibrosis indices were evaluated. The results demonstrated that HSYA can improve the general condition of rats with hepatic fibrosis and relieve cellular swelling of the liver, fatty degeneration, necrosis, inflammatory cell infiltration and fibroplastic proliferation. Subsequent to administration of HSYA, globulin was increased during hepatic fibrosis caused by tetrachloromethane. However, total cholesterol, triglyceride, alanine aminotransferase, aspartate aminotransferase and levels of hyaluronic acid, laminin, procollagen Ⅲ N‑terminal peptide, collagen type Ⅳ and hydroxyproline were significantly reduced. The results additionally demonstrated that HSYA could enhance superoxide dismutase activity and reduce malondialdehyde levels, inhibiting lipid peroxidation caused by free radicals.

View Figures

View References

1	Zois C, Baltayiannis G, Karayiannis P and Tsianos EV: Systematic review: Hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther. 28:1175–1187. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bralet MP: Image in pathology. Congenital hepatic fibrosis. Ann Pathol. 24:2842004.(In French). PubMed/NCBI
3	Cogliati B, Da Silva TC, Aloia TP, Chaible LM, Real-Lima MA, Sanches DS, Matsuzaki P, Hernandez-Blazquez FJ and Dagli ML: Morphological and molecular pathology of CCL₄-induced hepatic fibrosis in connexin43-deficient mice. Microsc Res Tech. 74:421–429. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wang L, Cheng D, Wang H, Di L, Zhou X, Xu T, Yang X and Liu Y: The hepatoprotective and antifibrotic effects of Saururus chinensis against carbon tetrachloride induced hepatic fibrosis in rats. J Ethnopharmacol. 126:487–491. 2009. View Article : Google Scholar : PubMed/NCBI
5	Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, et al: Multicentre clinical study On Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol. 11:2892–2899. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ru QJ, Tang ZM, Zhang ZE and Zhu Q: Clinical observation on effect of xuefu zhuyu decoction in treating patients with liver fibrosis caused by chronic hepatitis B. Chin J Integr Trad Western Med. 24:983–985. 2004.
7	Lu C, Shen Q, Yang J, Wang B and Song C: The complete chloroplast genome sequence of Safflower (Carthamus tinctorius L.). Mitochondrial DNA A DNA Mapp Seq Anal. 27:3351–3353. 2016.PubMed/NCBI
8	Zhao JF, Liu J, Guo Y, Liu Q, Dai Z, Ma SC and Lin RC: Chemical constituents from safflower injection and their bioactivity. Zhongguo Zhong Yao Za Zhi. 39:3102–3106. 2014.(In Chinese). PubMed/NCBI
9	Li Y, Chen Y, Wang L, Chen X, Liu X, Sun C and Yan W: Research on technological process of two-pot countercurrent extraction of hydroxysafflor yellow A. Zhongguo Zhong Yao Za Zhi. 34:2743–2747. 2009.PubMed/NCBI
10	Bie XD, Han J and Dai HB: Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats. J Asian Nat Prod Res. 12:239–247. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liu SX, Zhang Y, Wang YF, Li XC, Xiang MX, Bian C and Chen P: Upregulation of heme oxygenase-1 expression by hydroxysafflor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol. 160:95–101. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhu HJ, Wang LJ, Wang XQ, Pan H, Li NS, Yang HB, Jin M, Zang BX and Gong FY: Hormone-sensitive lipase is involved in the action of hydroxysafflor yellow A (HYSA) inhibiting adipogenesis of 3T3-L1cells. Fitoterapia. 93:182–188. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wang C, Huang Q, Wang C, Zhu X, Duan Y, Yuan S and Bai X: Hydroxysafflor yellow A suppresses oleic acid-induced acute lung injury via protein kinase A. Toxicol Appl Pharmacol. 272:895–904. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chobert MN, Couchie D, Fourcot A, Zafrani ES, Laperche Y, Mavier P and Brouillet A: Liver precursor cells increase hepatic fibrosis induced by chronic carbon tetrachloride intoxication in rats. Lab Invest. 92:135–150. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang XH, Lu XF, Liu CY, Hu SJ, Kang XX and Yang J: Diagnostics (8th). People's Health Publishing House. 3522015.(In Chinese).
16	Friedman SL: Hepatic fibrosis-overview. Toxicology. 254:120–129. 2008. View Article : Google Scholar : PubMed/NCBI
17	Guo J and Friedman SL: Hepatic fibmgenesis. Semin Liver Dis. 27:413–426. 2007. View Article : Google Scholar : PubMed/NCBI
18	Spengler U: Hepatic microcirculation: A critical but neglected factor for the outcome of viral hepatitis. J Hcpatol. 50:631–633. 2009.
19	Liu C, Wang G, Chen G, Mu Y, Zhang L, Hu X, Sun M, Liu C and Liu P: Huangqi decoction inhibils apoptosis and fibrosis, but promotes Kupffer cell activation in dimefhyllnitrosamine-induced rat liver fibrosis. BMC Complement Altern Med. 12:512012.PubMed/NCBI
20	Wang Q, Wen R, Lin Q, Wang N, Lu P and Zhu X: Wogonoside shows antifibrotic effects in an experimental regression model of hepatic fibrosis. Dig Dis Sci. 60:3329–3339. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yang F, Li J, Zhu J, Wang D, Chen S and Bai X: Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. Eur J Pharmacol. 754:105–114. 2015. View Article : Google Scholar : PubMed/NCBI
22	Liu C, Wang G, Chen G, Mu Y, Zhang L, Hu X, Sun M, Liu C and Liu P: Huangqi decoction inhibits apoptosis and fibrosis, but promotes Kupffer cell activation in dimethylnitrosamine-induced rat liver fibrosis. BMC Complement Altern Med. 12:512012.PubMed/NCBI
23	Yang XH, Wang DD and Zhu Y: Recent research progress on hydroxysafflor yellow A. J Trad Chin Med Univ Hunan. 33:102–106. 2013.(In Chinese).
24	Liu SY, Zhang YQ, Liu YL, Guo P and Zhou CM: Intervention of chronic hepatitis B liver fibrosis patients in different stages by syndrome typing and different activating blood removing stasis methods: A clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 33:1457–1461. 2013.(In Chinese). PubMed/NCBI
25	Shi XF, Xu M and Liu Q: The effects of total saponins of panax notoginseng on I, III-type collage and TGF in liver of cirrhosis rats. Zhongyao Yaoli Yu Linchuang. 17:7–8. 2001.
26	Wynn TA: Cellular and molecular mechanisms on fibrosis. J Pathl. 214:199–210. 2008. View Article : Google Scholar
27	Friedman SL, Rockey DC and Bissell DM: Hepatic fibrosis 2006: Report of the third SSALD single topic conference. Hepatology. 45:242–249. 2007. View Article : Google Scholar : PubMed/NCBI
28	Krählenbühl S, Reichen J, Zimmermann A, Gehr P and Stucki J: Mitochondrial structure and function in CCl₄-induced cirrhosis in the rat. Hepatology. 12:526–532. 1990. View Article : Google Scholar : PubMed/NCBI
29	Domitrović R, Rashed K, Cvijanović O, Vladimir-Knežević S, Škoda M and Višnić A: Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interact. 230:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
30	Wang ZB, Huang ZM, Wang JJ, Wu JM, Chen XR, Wu JS and Zhang QY: Inducing rat liver cirrhosis by adjusting the dosage of CCl₄ according to body weight changes. Zhonghua Gan Zang Bing Za Zhi. 16:234–235. 2008.(In Chinese). PubMed/NCBI
31	Gonzalez M, Sealls W, Jesch ED, Brosnan MJ, Ladunga I, Ding X, Black PN and DiRusso CC: Defining a relationship between dietary fatty acids and the cytochrome P450 system in a mouse model of fatty liver disease. Physiol Genomics. 43:121–135. 2011. View Article : Google Scholar : PubMed/NCBI
32	Wang CC, Lim LY, Deubner H, Tapia K, Lau AW, Manansala J, Krows M, Shuhart MC and Kowdley KV: Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol. 42:820–826. 2008. View Article : Google Scholar : PubMed/NCBI
33	Park JH, Park CK, Kim ES, Park SY, Jo CM, Tak WY, Kweon YO, Kim SK and Choi YW: The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients. Taehan Kan Hakhoe Chi. 9:79–88. 2003.PubMed/NCBI
34	Li CH, Piao DM, Xu WX, Yin ZR, Jin JS and Shen ZS: Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine-induced hepatic fibrosis of rats. World J Gastroenterol. 11:7620–7624. 2005. View Article : Google Scholar : PubMed/NCBI
35	Khan JA, Khan FA, Dilawar M, Ijaz A, Khan NA and Mehmood T: Serum hyaluronic acid as a marker of hepatic fibrosis. J Coll Physicians Surg Pak. 17:323–326. 2007.PubMed/NCBI
36	Geramizadeh B, Janfeshan K and Saberfiroozi M: Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 14:174–177. 2008. View Article : Google Scholar : PubMed/NCBI
37	Huang Z, Li Q and Wang Z: Observation on dynamic changes of serum procollagen III, hyaluronic acid and laminin in rats with hepatic fibrosis treated with Hujin pill. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:447–449. 2000.(In Chinese). PubMed/NCBI
38	Tsutsumi M, Takase S, Urashima S, Ueshima Y, Kawahara H and Takada A: Serum markers for hepatic fibrosis in alcoholic liver disease: Which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase? Alcohol Clin Exp Res. 20:1512–1517. 1996. View Article : Google Scholar : PubMed/NCBI
39	Iushchuk ND, Znoĭko OO, Safiullina NKh, Dudina KR, Kelli EI, Klimova EA, Kashirin VI, Braginskiĭ DM, Kushlinskiĭ NE, Liubimova NV, et al: Diagnostic significance of type IV collagen and hyaluronic acid in the serum of patients with chronic hepatitis C for staging hepatic fibrosis. Ter Arkh. 77:50–55. 2005.(In Russian).
40	Toyoki Y, Sasaki M, Narumi S, Yoshihara S, Morita T and Konn M: Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline. Hepatogastroenterology. 45:2261–2264. 1998.PubMed/NCBI
41	Liu J, Tan H, Sun Y, Zhou S, Cao J and Wang F: The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol Cell Biochem. 327:219–228. 2009. View Article : Google Scholar : PubMed/NCBI
42	Huang Q, Li Y, Zhang S, Huang R, Zheng L, Wei L, He M, Liao M, Li L, Zhuo L and Lin X: Effect and mechanism of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol. 143:889–895. 2012. View Article : Google Scholar : PubMed/NCBI
43	Kanno K, Tazuma S and Chayama K: AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun. 308:177–183. 2003. View Article : Google Scholar : PubMed/NCBI
44	Smyth R, Munday MR, York MJ, Clarke CJ, Dare T and Turton JA: Comprehensive characterization of serum clinical chemistry parameters and the identification of urinary superoxide dismutase in a carbon tetrachloride-induced model of hepatic fibrosis in the female Hanover Wistar rat. Int J Exp Pathol. 88:361–376. 2007. View Article : Google Scholar : PubMed/NCBI
45	Yu J, Wang Y, Qian H, Zhao Y, Liu B and Fu C: Polyprenols from Taxus chinensis var. mairei prevent the development of CCl₄-induced liver fibrosis in rats. J Ethnopharmacol. 142:151–160. 2012. View Article : Google Scholar : PubMed/NCBI
46	Liu J, Tan H, Sun Y, Zhou S, Cao J and Wang F: The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol Cell Biochem. 327:219–228. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ljubuncic P, Abu-Salach O and Bomzon A: Ursodeoxycholic acid and superoxide anion. World J Gastroenterol. 11:4875–4878. 2005. View Article : Google Scholar : PubMed/NCBI